nach oben

Annals of Nuclear Medicine

Erschienen in:

01.10.2011 | Original article

Evaluation of lung epithelial permeability in the volatile substance abuse using Tc-99m DTPA aerosol scintigraphy

verfasst von: Derya Cayir, Koray Demirel, Meliha Korkmaz, Gokhan Koca

Erschienen in: Annals of Nuclear Medicine | Ausgabe 8/2011

Einloggen, um Zugang zu erhalten

Abstract

Aim

Chronic inhalant use is associated with significant toxic effects, including neurological, renal, hepatic, and pulmonary damage. However, there is a paucity of reports regarding respiratory complications in inhalant abusers. The aim of this study was to evaluate pulmonary epithelial permeability in the volatile substance abuse (VSA) using Tc-99m DTPA aerosol scintigraphy.

Methods

This study included 18 patients with volatile substance abuse and 18 volunteer controls. All of patients and controls were smokers. Tc-99m DTPA aerosol scintigraphy was performed in all cases. Time-activity curves from each lung were generated and clearance half-time (T _1/2) of Tc-99m DTPA were calculated. T _1/2 of whole lung was calculated as a mean of the T _1/2 of left and right lung.

Results

The T _1/2 values of Tc-99m DTPA clearance in the substance abusers were significantly decreased as compared to the control group with respective mean values of 28.86 ± 8.44, and 62.14 ± 26.12 min (p = 0.001). It was seen Tc-99m DTPA clearance from lung was faster as the duration of substance abuse was increased.

Conclusions

Tc-99m DTPA pulmonary clearance is markedly accelerated in the volatile substance abuse. This suggests that inhalant abuse of substance may produce abnormalities in pulmonary alveolo-capillary membrane function.

Field-Smith ME, Butland BK, Ramsey JD, Anderson HR. Trends in death associated with abuse of volatile substances 1971–2007, report 22. London: Division of Community Health Sciences, St George’s, University of London; 2009. http://www.vsareport.org. Accessed 15 March 2010.

Lubman DI, Yucel M, Lawrence AJ, et al. Inhalant abuse among adolescents: neurobiological considerations. Br J Pharmacol. 2008;154:316–26.PubMedCrossRef

Ramon MF, Ballesteros S, Martinez-Arrieta R, Torrecilla JM, Cabrera J. Volatile substance and other drug abuse inhalation in Spain. J Toxicol Clin Toxicol. 2003;41:931–6.PubMedCrossRef

Schuckit MA. Glues, inhalants, and aerosols drug. In: Drug and alcohol abuse, a clinical guide to diagnosis and treatment. 6th edn. New York: Springer; 2006. p. 236–47.

Crowe AV, Howse M, Bell GM, Henry JA. Substance abuse and the kidney. QJM. 2000;93:147–52.PubMedCrossRef

Pearson MA, Hoyme HE, Seaver LH, Rimsza ME. Toluene embryopathy: delineation of the phenotype and comparison with fetal alcohol syndrome. Pediatrics. 1994;93:211–5.PubMed

Hormes JT, Filley CM, Rosenberg NL. Neurologic sequelae of chronic solvent vapor abuse. Neurology. 1986;36:698–702.PubMed

Williams JF, Storck M. Committee on Substance Abuse, Committee on Native American Child Health. Inhalant abuse. Pediatrics. 2007;119:1009–17.PubMedCrossRef

Lorenc JD. Inhalant abuse in the pediatric population: a persistent challenge. Curr Opin Pediatr. 2003;15:204–9.PubMedCrossRef

10.

Uzun N, Kendirli Y. Clinical, socio-demographic, neurophysiological and neuropsychiatric evaluation of children with volatile substance addiction. Child Care Health Dev. 2005;31:425–32.PubMedCrossRef

11.

Reyes de la Rocha S, Brown MA, Fortenberry JD, et al. Pulmonary function abnormalities in intentional spray paint inhalation. Chest. 1987;92:100–4.PubMedCrossRef

12.

Marjot R, McLeod AA. Chronic non-neurological toxicity from volatile substance abuse. Hum Toxicol. 1989;8:301–6.PubMedCrossRef

13.

Dinwiddie SH. Abuse of inhalants: a review. Addiction. 1994;89:925–39.PubMedCrossRef

14.

Kurtzman TL, Otsuka KN, Wahl RA. Inhalant abuse by adolescents. J Adolesc Health. 2001;28:170–80.PubMedCrossRef

15.

Sundram FX. Clinical studies of alveolar-capillary permeability using technetium-99m DTPA aerosol. Ann Nucl Med. 1995;9:171–8.PubMedCrossRef

16.

Coates G, O’Brodovich H. Measurement of pulmonary epithelial permeability with 99mTc-DTPA aerosol. Semin Nucl Med. 1986;16:275–84.PubMedCrossRef

17.

O’Doherty MJ, Peters AM. Pulmonary technetium-99m diethylene triamine penta-acetic acid aerosol clearance as an index of lung injury. Eur J Nucl Med. 1997;24:81–7.PubMedCrossRef

18.

Smith RJ, Hyde RW, Waldman DL, Freund GG, Weber DA, Utell MJ, et al. Effect of pattern of aerosol inhalation on clearance of technetium-99m-labeled diethylenetriamine pentaacetic acid from the lungs of normal humans. Am Rev Respir Dis. 1992;145:1109–16.PubMedCrossRef

19.

O’Brodovich H, Coates G. Pulmonary clearance of 99mTc-DTPA: a noninvasive assessment of epithelial integrity. Lung. 1987;165:1–16.PubMedCrossRef

20.

Staub NC, Hyde RW, Crandall E. NHLBI workshop summary. Workshop on techniques to evaluate lung alveolar-microvascular injury. Am Rev Respir Dis. 1990;141:1071–7.PubMed

21.

Anderson CE, Loomis GA. Recognition and prevention of inhalant abuse. Am Fam Physician. 2003;68:869–74.PubMed

22.

Patel R, Benjamin J. Renal disease associated with toluene inhalation. J Toxicol Clin Toxicol. 1986;24:213–23.PubMedCrossRef

23.

King MD, Day RE, Oliver JS, Lush M, Watson JM. Solvent encephalopaty. Br Med J. 1981;283:663–5.CrossRef

24.

Sharp CW, Rosenberg NL. Inhalants. In: Lowinson JH, Ruiz P, Millman RB, Langrod JG, editors. Substance abuse. A comprehensive textbook. 4th ed. Baltimore: Williams and Wilkins; 2004. p. 336–66.

25.

Panson RD, Winek CL. Aspiration toxicity of ketones. Clin Toxicol. 1980;17:271–317.PubMedCrossRef

26.

Schikler KN, Lane EE, Seitz K, Collins WM. Solvent abuse associated pulmonary abnormalities. Adv Alcohol Subst Abuse. 1984;3:75–81.PubMedCrossRef

27.

Robert R, Touchard G, Meurice JC, Pourrat O, Yver L. Severe Goodpasture’s syndrome after glue sniffing. Nephrol Dial Transplant. 1988;3:483–4.PubMed

28.

Lin WY, Kao CH, Wang SJ. Detection of acute inhalation injury in fire victims by means of technetium-99m DTPA radioaerosol inhalation lung scintigraphy. Eur J Nucl Med. 1997;24:125–9.PubMedCrossRef

29.

Pantin CF, Valind SO, Sweatman M, Lawrence R, Rhodes CG, Brudin L, et al. Measures of the inflammatory response in cryptogenic fibrosing alveolitis. Am Rev Respir Dis. 1988;138:1234–41.PubMed

30.

Susskind H. Technetium-99m-DTPA aerosol to measure alveolar-capillary membrane permeability. J Nucl Med. 1994;35:207–9.PubMed

31.

Jones JG, Minty BD, Lawler P, Hulands G, Crawley JC, Veall N. Increased alveolar epithelial permeability in cigarette smokers. Lancet. 1980;1:66–8.PubMedCrossRef

32.

Schmekel B, Bos JA, Khan AR, Wohlfart B, Lachmann B, Wollmer P. Integrity of the alveolar-capillary barrier and alveolar surfactant system in smokers. Thorax. 1992;47:603–8.PubMedCrossRef

33.

Isawa T. Anatomy and physiology. In: Bahk YW, Kim EE, Isawa T, editors. Nuclear imaging of the chest. Berlin: Springer; 1998, p. 9–30.

34.

Monaghan P, Provan I, Murray C, Mackey DW, Van der Wall H, Walker BM, et al. An improved radionuclide technique for the detection of altered pulmonary permeability. J Nucl Med. 1991;32:1945–9.PubMed

35.

Mason GR, Uszler JM, Effros RM, Reid E. Rapidly reversible alterations of pulmonary epithelial permeability induced by smoking. Chest. 1983;83:6–11.PubMedCrossRef

36.

Kaya M, Salan A, Tabakoglu E, Aydogdu N, Berkarda S. The bronchoalveolar epithelial permeability in house painters as determined by Tc-99m DTPA aerosol scintigraphy. Ann Nucl Med. 2003;17:305–8.PubMedCrossRef

37.

Cerci SS, Ozturk O, Sutcu R, Ozbek FM, Baydar CL, Yildiz M, et al. Evaluation of the effects of toluene inhalation on alveolar epithelial permeability by 99mTc-DTPA inhalation scintigraphy in automobile painters. Nucl Med Commun. 2008;29:45–52.PubMedCrossRef

38.

Press E, Done AK. Solvent sniffing. Physiologic effects and community control measures for intoxication from the intentional inhalation of organic solvents. II. Pediatrics. 1967;39:611–22.PubMed

39.

Musclow CE, Awen CF. Glue sniffing: report of a fatal case. Can Med Assoc J. 1971;104:315–9.PubMed

Titel: Evaluation of lung epithelial permeability in the volatile substance abuse using Tc-99m DTPA aerosol scintigraphy
verfasst von: Derya Cayir
Koray Demirel
Meliha Korkmaz
Gokhan Koca
Publikationsdatum: 01.10.2011
Verlag: Springer Japan
Erschienen in: Annals of Nuclear Medicine / Ausgabe 8/2011
Print ISSN: 0914-7187
Elektronische ISSN: 1864-6433
DOI: https://doi.org/10.1007/s12149-011-0498-7

Springer Medizin

Abstract

Aim

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 8/2011

Quantification of myocardial perfusion SPECT using freeware package (cardioBull)

Quantification of [18F]-FDG uptake in atherosclerotic plaque: impact of renal function

Internal radiotherapy techniques using radiolanthanide praseodymium-142: a review of production routes, brachytherapy, unsealed source therapy

Accelerated BMIPP uptake immediately after reperfused ischemia in the isolated rat heart model

Demonstrations of AIDS-associated malignancies and infections at FDG PET-CT

18F-FDG uptake in primary lung cancer as a predictor of intratumoral vessel invasion